| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vaccines | 10 | 2024 | 225 | 2.860 |
Why?
|
| Immunologic Factors | 3 | 2026 | 35 | 2.660 |
Why?
|
| Vaccination | 16 | 2026 | 726 | 2.230 |
Why?
|
| Humans | 107 | 2026 | 17622 | 2.180 |
Why?
|
| Rituximab | 3 | 2026 | 20 | 2.050 |
Why?
|
| Retrospective Studies | 41 | 2026 | 2502 | 1.990 |
Why?
|
| Male | 75 | 2026 | 10014 | 1.920 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 2 | 2026 | 20 | 1.850 |
Why?
|
| Female | 77 | 2026 | 12715 | 1.770 |
Why?
|
| Middle Aged | 49 | 2026 | 7954 | 1.700 |
Why?
|
| Adult | 47 | 2026 | 7621 | 1.680 |
Why?
|
| Models, Statistical | 6 | 2014 | 171 | 1.560 |
Why?
|
| Multiple Sclerosis | 2 | 2025 | 102 | 1.500 |
Why?
|
| Influenza Vaccines | 10 | 2025 | 301 | 1.480 |
Why?
|
| Aged | 40 | 2026 | 6223 | 1.380 |
Why?
|
| Disease Progression | 4 | 2026 | 266 | 1.310 |
Why?
|
| Telemedicine | 3 | 2024 | 196 | 1.260 |
Why?
|
| Adolescent | 25 | 2025 | 3625 | 1.220 |
Why?
|
| Young Adult | 22 | 2026 | 2538 | 1.180 |
Why?
|
| United States | 39 | 2026 | 3922 | 1.160 |
Why?
|
| Computer Simulation | 8 | 2016 | 85 | 1.160 |
Why?
|
| Pandemics | 4 | 2024 | 295 | 1.080 |
Why?
|
| Vaccination Coverage | 2 | 2025 | 63 | 1.050 |
Why?
|
| Algorithms | 4 | 2025 | 227 | 1.020 |
Why?
|
| Electronic Health Records | 9 | 2025 | 719 | 1.010 |
Why?
|
| Depression | 5 | 2017 | 507 | 1.000 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 5 | 2017 | 84 | 1.000 |
Why?
|
| Hypertension | 5 | 2021 | 486 | 0.990 |
Why?
|
| Tinnitus | 1 | 2025 | 2 | 0.920 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2024 | 380 | 0.910 |
Why?
|
| Residence Characteristics | 3 | 2024 | 256 | 0.900 |
Why?
|
| Emergency Service, Hospital | 6 | 2024 | 402 | 0.890 |
Why?
|
| Asthma | 3 | 2024 | 401 | 0.880 |
Why?
|
| Cohort Studies | 28 | 2026 | 2502 | 0.860 |
Why?
|
| Ticlopidine | 3 | 2014 | 16 | 0.850 |
Why?
|
| Crime | 1 | 2024 | 23 | 0.850 |
Why?
|
| Agammaglobulinemia | 1 | 2024 | 2 | 0.840 |
Why?
|
| Healthcare Disparities | 2 | 2025 | 208 | 0.830 |
Why?
|
| Incidence | 18 | 2024 | 1278 | 0.820 |
Why?
|
| Thrombocytopenia | 2 | 2022 | 17 | 0.820 |
Why?
|
| California | 6 | 2025 | 2433 | 0.810 |
Why?
|
| Hyperkalemia | 4 | 2010 | 15 | 0.790 |
Why?
|
| Cataplexy | 1 | 2022 | 6 | 0.730 |
Why?
|
| Narcolepsy | 1 | 2022 | 8 | 0.730 |
Why?
|
| Bell Palsy | 1 | 2022 | 14 | 0.730 |
Why?
|
| Sociological Factors | 1 | 2021 | 2 | 0.680 |
Why?
|
| Confounding Factors (Epidemiology) | 4 | 2016 | 82 | 0.680 |
Why?
|
| Mortality | 1 | 2021 | 116 | 0.670 |
Why?
|
| Outpatients | 2 | 2021 | 103 | 0.660 |
Why?
|
| Primary Health Care | 6 | 2020 | 729 | 0.660 |
Why?
|
| Hemorrhage | 3 | 2016 | 62 | 0.650 |
Why?
|
| Inpatients | 1 | 2021 | 78 | 0.650 |
Why?
|
| Risk Factors | 16 | 2025 | 3291 | 0.640 |
Why?
|
| Delivery of Health Care, Integrated | 4 | 2021 | 540 | 0.640 |
Why?
|
| Child | 16 | 2024 | 2485 | 0.610 |
Why?
|
| Proportional Hazards Models | 7 | 2021 | 702 | 0.600 |
Why?
|
| Antihypertensive Agents | 3 | 2017 | 163 | 0.600 |
Why?
|
| Influenza, Human | 7 | 2023 | 294 | 0.590 |
Why?
|
| RNA, Messenger | 4 | 2023 | 72 | 0.580 |
Why?
|
| Clinical Trials as Topic | 2 | 2010 | 121 | 0.560 |
Why?
|
| Potassium | 4 | 2010 | 14 | 0.560 |
Why?
|
| Drug Overdose | 3 | 2026 | 64 | 0.550 |
Why?
|
| Opioid-Related Disorders | 4 | 2026 | 185 | 0.540 |
Why?
|
| Hypoglycemic Agents | 6 | 2017 | 259 | 0.540 |
Why?
|
| Models, Theoretical | 3 | 2016 | 67 | 0.530 |
Why?
|
| Diabetes Mellitus, Type 1 | 4 | 2021 | 120 | 0.520 |
Why?
|
| Antidepressive Agents | 3 | 2014 | 142 | 0.520 |
Why?
|
| Risk Assessment | 7 | 2020 | 1093 | 0.520 |
Why?
|
| Calcium Channel Blockers | 1 | 2017 | 15 | 0.510 |
Why?
|
| Risk | 6 | 2021 | 492 | 0.510 |
Why?
|
| Telephone | 6 | 2015 | 159 | 0.500 |
Why?
|
| Infant | 17 | 2021 | 1228 | 0.500 |
Why?
|
| Insurance, Health | 2 | 2026 | 169 | 0.500 |
Why?
|
| Health Services | 3 | 2013 | 110 | 0.490 |
Why?
|
| Odds Ratio | 5 | 2021 | 631 | 0.490 |
Why?
|
| Child, Preschool | 16 | 2021 | 1455 | 0.490 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 23 | 0.480 |
Why?
|
| Internet | 3 | 2017 | 207 | 0.480 |
Why?
|
| Biometry | 2 | 2014 | 13 | 0.470 |
Why?
|
| Time Factors | 12 | 2017 | 1038 | 0.470 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2016 | 64 | 0.460 |
Why?
|
| Diabetes Mellitus | 7 | 2014 | 452 | 0.450 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2014 | 24 | 0.450 |
Why?
|
| Rural Health Services | 3 | 2010 | 13 | 0.450 |
Why?
|
| Observational Studies as Topic | 2 | 2016 | 46 | 0.440 |
Why?
|
| Absenteeism | 1 | 2014 | 21 | 0.440 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 6 | 2021 | 64 | 0.440 |
Why?
|
| Group Purchasing | 1 | 2014 | 1 | 0.440 |
Why?
|
| Decision Making, Organizational | 1 | 2014 | 3 | 0.440 |
Why?
|
| Occupational Health | 1 | 2014 | 16 | 0.430 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2014 | 16 | 0.430 |
Why?
|
| Safety | 2 | 2014 | 43 | 0.430 |
Why?
|
| Employment | 1 | 2014 | 44 | 0.430 |
Why?
|
| Immunization Schedule | 6 | 2021 | 127 | 0.420 |
Why?
|
| Patient Compliance | 1 | 2016 | 269 | 0.420 |
Why?
|
| Disease Management | 3 | 2015 | 110 | 0.420 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 3 | 2010 | 11 | 0.410 |
Why?
|
| Counseling | 3 | 2014 | 173 | 0.410 |
Why?
|
| Confidence Intervals | 5 | 2021 | 228 | 0.390 |
Why?
|
| Renin-Angiotensin System | 2 | 2010 | 16 | 0.390 |
Why?
|
| Access to Information | 1 | 2012 | 12 | 0.380 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2010 | 53 | 0.370 |
Why?
|
| Urban Health Services | 2 | 2010 | 11 | 0.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 6 | 2017 | 689 | 0.370 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2013 | 96 | 0.370 |
Why?
|
| Aged, 80 and over | 12 | 2026 | 1976 | 0.360 |
Why?
|
| Medication Adherence | 5 | 2020 | 232 | 0.360 |
Why?
|
| Delivery of Health Care | 4 | 2023 | 383 | 0.360 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 109 | 0.360 |
Why?
|
| Vaccines, Inactivated | 4 | 2020 | 73 | 0.350 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2011 | 120 | 0.340 |
Why?
|
| Overweight | 2 | 2014 | 266 | 0.340 |
Why?
|
| Epidemiologic Research Design | 1 | 2010 | 18 | 0.330 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2010 | 67 | 0.320 |
Why?
|
| Analgesics, Opioid | 3 | 2023 | 258 | 0.320 |
Why?
|
| Research Design | 3 | 2024 | 337 | 0.320 |
Why?
|
| Hospitalization | 7 | 2015 | 831 | 0.310 |
Why?
|
| Colorado | 9 | 2020 | 170 | 0.310 |
Why?
|
| Text Messaging | 2 | 2020 | 38 | 0.300 |
Why?
|
| Ambulatory Care | 4 | 2020 | 228 | 0.290 |
Why?
|
| Bias | 4 | 2019 | 95 | 0.290 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1005 | 0.290 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1295 | 0.290 |
Why?
|
| Socioeconomic Factors | 3 | 2024 | 603 | 0.280 |
Why?
|
| Depressive Disorder | 4 | 2014 | 186 | 0.280 |
Why?
|
| Parents | 2 | 2015 | 301 | 0.260 |
Why?
|
| Myocardial Infarction | 4 | 2015 | 226 | 0.260 |
Why?
|
| Age Factors | 6 | 2020 | 874 | 0.250 |
Why?
|
| Vaccines, Combined | 2 | 2023 | 81 | 0.250 |
Why?
|
| Naltrexone | 1 | 2026 | 18 | 0.240 |
Why?
|
| Urban Population | 3 | 2021 | 111 | 0.240 |
Why?
|
| Treatment Outcome | 4 | 2025 | 1161 | 0.240 |
Why?
|
| Narcotic Antagonists | 1 | 2026 | 23 | 0.230 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2017 | 157 | 0.230 |
Why?
|
| Drug Administration Schedule | 1 | 2025 | 99 | 0.230 |
Why?
|
| Opiate Substitution Treatment | 1 | 2026 | 55 | 0.230 |
Why?
|
| Buprenorphine | 1 | 2026 | 53 | 0.230 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2026 | 107 | 0.230 |
Why?
|
| Propensity Score | 3 | 2016 | 80 | 0.220 |
Why?
|
| Seizures | 2 | 2015 | 28 | 0.220 |
Why?
|
| Drug-Eluting Stents | 3 | 2014 | 7 | 0.210 |
Why?
|
| Immunoglobulin G | 1 | 2024 | 35 | 0.210 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 39 | 0.200 |
Why?
|
| Health Behavior | 4 | 2014 | 348 | 0.200 |
Why?
|
| Respiratory Insufficiency | 1 | 2023 | 16 | 0.200 |
Why?
|
| Noninvasive Ventilation | 1 | 2023 | 11 | 0.190 |
Why?
|
| Urticaria | 1 | 2022 | 2 | 0.190 |
Why?
|
| Exanthema | 1 | 2022 | 7 | 0.190 |
Why?
|
| Infant, Newborn | 4 | 2021 | 842 | 0.190 |
Why?
|
| Myocarditis | 1 | 2022 | 14 | 0.190 |
Why?
|
| Dermatitis, Atopic | 1 | 2022 | 18 | 0.190 |
Why?
|
| Stroke | 2 | 2023 | 309 | 0.190 |
Why?
|
| Case-Control Studies | 7 | 2020 | 1107 | 0.190 |
Why?
|
| Data Interpretation, Statistical | 4 | 2021 | 69 | 0.180 |
Why?
|
| Aluminum | 1 | 2021 | 15 | 0.180 |
Why?
|
| Atrial Fibrillation | 1 | 2023 | 173 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2014 | 161 | 0.170 |
Why?
|
| New Mexico | 1 | 2021 | 6 | 0.170 |
Why?
|
| Medicare | 3 | 2026 | 197 | 0.170 |
Why?
|
| Heroin | 1 | 2020 | 5 | 0.160 |
Why?
|
| Heroin Dependence | 1 | 2020 | 5 | 0.160 |
Why?
|
| Prospective Studies | 3 | 2021 | 1251 | 0.160 |
Why?
|
| Withholding Treatment | 1 | 2020 | 26 | 0.160 |
Why?
|
| Spironolactone | 2 | 2010 | 7 | 0.160 |
Why?
|
| Registries | 5 | 2015 | 475 | 0.160 |
Why?
|
| Nurse-Patient Relations | 1 | 2020 | 8 | 0.160 |
Why?
|
| Criminal Law | 1 | 2020 | 13 | 0.160 |
Why?
|
| Rural Population | 3 | 2011 | 58 | 0.160 |
Why?
|
| Integrative Medicine | 1 | 2020 | 6 | 0.160 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2020 | 33 | 0.160 |
Why?
|
| Acute Pain | 1 | 2020 | 11 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2020 | 15 | 0.160 |
Why?
|
| Vaccines, Attenuated | 1 | 2020 | 44 | 0.160 |
Why?
|
| Workload | 1 | 2020 | 26 | 0.160 |
Why?
|
| Schizophrenia | 2 | 2011 | 76 | 0.160 |
Why?
|
| Drug Monitoring | 2 | 2010 | 20 | 0.160 |
Why?
|
| Rotavirus Vaccines | 1 | 2020 | 53 | 0.150 |
Why?
|
| Complementary Therapies | 1 | 2020 | 41 | 0.150 |
Why?
|
| Electronic Mail | 1 | 2020 | 51 | 0.150 |
Why?
|
| Reminder Systems | 2 | 2015 | 76 | 0.150 |
Why?
|
| Metformin | 2 | 2017 | 52 | 0.150 |
Why?
|
| Prisoners | 1 | 2020 | 54 | 0.150 |
Why?
|
| Insulin | 2 | 2017 | 188 | 0.150 |
Why?
|
| Follow-Up Studies | 7 | 2020 | 1157 | 0.140 |
Why?
|
| Population Surveillance | 4 | 2011 | 248 | 0.140 |
Why?
|
| Chronic Pain | 1 | 2020 | 133 | 0.140 |
Why?
|
| HIV Infections | 1 | 2024 | 584 | 0.140 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 686 | 0.140 |
Why?
|
| Regression Analysis | 3 | 2016 | 268 | 0.140 |
Why?
|
| Health Maintenance Organizations | 5 | 2012 | 403 | 0.140 |
Why?
|
| Blood Glucose | 3 | 2015 | 319 | 0.140 |
Why?
|
| Survival Analysis | 2 | 2017 | 197 | 0.140 |
Why?
|
| Growth Substances | 1 | 1998 | 1 | 0.140 |
Why?
|
| Pulmonary Alveoli | 1 | 1998 | 2 | 0.140 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 13 | 0.140 |
Why?
|
| Pulmonary Surfactants | 1 | 1998 | 4 | 0.140 |
Why?
|
| Sex Factors | 3 | 2021 | 599 | 0.140 |
Why?
|
| Comorbidity | 4 | 2016 | 552 | 0.130 |
Why?
|
| Hospital Mortality | 3 | 2022 | 135 | 0.130 |
Why?
|
| Managed Care Programs | 3 | 2017 | 300 | 0.130 |
Why?
|
| Social Media | 1 | 2017 | 11 | 0.130 |
Why?
|
| Information Dissemination | 1 | 2017 | 50 | 0.130 |
Why?
|
| Surveys and Questionnaires | 4 | 2020 | 1296 | 0.130 |
Why?
|
| Models, Biological | 1 | 2017 | 27 | 0.130 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 346 | 0.130 |
Why?
|
| Wounds and Injuries | 2 | 2007 | 43 | 0.120 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2016 | 55 | 0.120 |
Why?
|
| Costs and Cost Analysis | 2 | 2014 | 65 | 0.120 |
Why?
|
| Diffusion of Innovation | 1 | 2016 | 36 | 0.120 |
Why?
|
| User-Computer Interface | 1 | 2015 | 22 | 0.120 |
Why?
|
| Fitness Centers | 1 | 2015 | 10 | 0.120 |
Why?
|
| Intellectual Disability | 1 | 2015 | 28 | 0.110 |
Why?
|
| Speech Recognition Software | 1 | 2015 | 2 | 0.110 |
Why?
|
| Medical Records | 1 | 2015 | 91 | 0.110 |
Why?
|
| Pregnancy Outcome | 1 | 2016 | 162 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2015 | 23 | 0.110 |
Why?
|
| Diabetic Nephropathies | 1 | 2015 | 25 | 0.110 |
Why?
|
| Presenteeism | 1 | 2014 | 2 | 0.110 |
Why?
|
| Diabetic Angiopathies | 1 | 2015 | 33 | 0.110 |
Why?
|
| Blood Chemical Analysis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Heart Diseases | 1 | 2015 | 71 | 0.110 |
Why?
|
| Risk Reduction Behavior | 1 | 2015 | 102 | 0.110 |
Why?
|
| Logistic Models | 5 | 2011 | 866 | 0.110 |
Why?
|
| Premature Birth | 1 | 2016 | 136 | 0.110 |
Why?
|
| Health Surveys | 1 | 2015 | 242 | 0.110 |
Why?
|
| Monitoring, Physiologic | 1 | 2014 | 35 | 0.110 |
Why?
|
| Commerce | 1 | 2014 | 37 | 0.110 |
Why?
|
| Office Visits | 2 | 2012 | 75 | 0.110 |
Why?
|
| Pharmacoepidemiology | 1 | 2014 | 18 | 0.100 |
Why?
|
| Prescription Drugs | 1 | 2014 | 30 | 0.100 |
Why?
|
| Glycated Hemoglobin A | 4 | 2015 | 179 | 0.100 |
Why?
|
| Coronary Angiography | 1 | 2013 | 17 | 0.100 |
Why?
|
| Fee-for-Service Plans | 1 | 2013 | 21 | 0.100 |
Why?
|
| Medicare Part C | 1 | 2013 | 11 | 0.100 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2013 | 23 | 0.100 |
Why?
|
| Coronary Artery Bypass | 1 | 2013 | 25 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2014 | 319 | 0.100 |
Why?
|
| Databases, Factual | 2 | 2016 | 304 | 0.100 |
Why?
|
| After-Hours Care | 1 | 2012 | 2 | 0.100 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2015 | 187 | 0.100 |
Why?
|
| Data Mining | 2 | 2022 | 17 | 0.100 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 237 | 0.090 |
Why?
|
| Seasons | 1 | 2013 | 116 | 0.090 |
Why?
|
| Smoking | 1 | 2015 | 420 | 0.090 |
Why?
|
| Adrenal Cortex Hormones | 2 | 2022 | 67 | 0.090 |
Why?
|
| Biostatistics | 1 | 2012 | 11 | 0.090 |
Why?
|
| Life Style | 1 | 2014 | 321 | 0.090 |
Why?
|
| Radiography, Interventional | 1 | 2012 | 1 | 0.090 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2012 | 2 | 0.090 |
Why?
|
| Hospitals, University | 1 | 2012 | 14 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2023 | 125 | 0.090 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2012 | 10 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2012 | 57 | 0.090 |
Why?
|
| Catheter Ablation | 1 | 2012 | 11 | 0.090 |
Why?
|
| Anemia, Sickle Cell | 1 | 2011 | 7 | 0.090 |
Why?
|
| Motor Activity | 2 | 2015 | 207 | 0.090 |
Why?
|
| Health Services Needs and Demand | 2 | 2010 | 88 | 0.090 |
Why?
|
| Exercise | 2 | 2015 | 538 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2012 | 22 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2012 | 37 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 293 | 0.090 |
Why?
|
| Liver Neoplasms | 1 | 2012 | 36 | 0.090 |
Why?
|
| Schizophrenic Psychology | 1 | 2011 | 5 | 0.090 |
Why?
|
| Hypolipidemic Agents | 1 | 2011 | 37 | 0.090 |
Why?
|
| False Negative Reactions | 1 | 2010 | 12 | 0.080 |
Why?
|
| False Positive Reactions | 1 | 2010 | 26 | 0.080 |
Why?
|
| Automation | 1 | 2010 | 24 | 0.080 |
Why?
|
| Blood Pressure | 3 | 2020 | 288 | 0.080 |
Why?
|
| Antipsychotic Agents | 1 | 2011 | 50 | 0.080 |
Why?
|
| Cause of Death | 2 | 2026 | 179 | 0.080 |
Why?
|
| African Continental Ancestry Group | 1 | 2011 | 140 | 0.080 |
Why?
|
| Coronary Artery Disease | 1 | 2011 | 112 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2011 | 107 | 0.080 |
Why?
|
| Prosthesis Implantation | 1 | 2010 | 8 | 0.080 |
Why?
|
| Postoperative Hemorrhage | 1 | 2010 | 8 | 0.080 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 545 | 0.080 |
Why?
|
| Employer Health Costs | 1 | 2010 | 2 | 0.080 |
Why?
|
| Epidemiologic Methods | 3 | 2019 | 70 | 0.080 |
Why?
|
| Selection Bias | 1 | 2009 | 16 | 0.080 |
Why?
|
| Sample Size | 1 | 2009 | 27 | 0.080 |
Why?
|
| Public Health Surveillance | 2 | 2020 | 42 | 0.080 |
Why?
|
| Prevalence | 3 | 2017 | 830 | 0.080 |
Why?
|
| Monitoring, Ambulatory | 1 | 2009 | 18 | 0.080 |
Why?
|
| Cost of Illness | 1 | 2010 | 92 | 0.070 |
Why?
|
| Maternal Age | 2 | 2021 | 74 | 0.070 |
Why?
|
| Hispanic Americans | 1 | 2011 | 370 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2009 | 103 | 0.070 |
Why?
|
| European Continental Ancestry Group | 1 | 2011 | 470 | 0.070 |
Why?
|
| Pregnancy | 4 | 2017 | 1565 | 0.070 |
Why?
|
| Feeding and Eating Disorders | 1 | 2009 | 16 | 0.070 |
Why?
|
| Drug Evaluation | 1 | 2008 | 6 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic | 1 | 2008 | 2 | 0.070 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 19 | 0.070 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2008 | 5 | 0.070 |
Why?
|
| Pneumococcal Vaccines | 2 | 2005 | 68 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2010 | 260 | 0.070 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2005 | 213 | 0.070 |
Why?
|
| Normal Distribution | 1 | 2007 | 6 | 0.070 |
Why?
|
| Public Health Informatics | 1 | 2007 | 7 | 0.070 |
Why?
|
| Software | 1 | 2007 | 19 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2007 | 11 | 0.060 |
Why?
|
| Parent-Child Relations | 1 | 2007 | 55 | 0.060 |
Why?
|
| Diet | 1 | 2009 | 355 | 0.060 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2006 | 3 | 0.060 |
Why?
|
| Alcoholic Intoxication | 1 | 2006 | 6 | 0.060 |
Why?
|
| Weight Loss | 1 | 2009 | 298 | 0.060 |
Why?
|
| Multivariate Analysis | 4 | 2010 | 527 | 0.060 |
Why?
|
| Likelihood Functions | 1 | 2006 | 45 | 0.060 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 59 | 0.060 |
Why?
|
| Depressive Disorder, Major | 1 | 2007 | 98 | 0.060 |
Why?
|
| Child Health Services | 1 | 2007 | 107 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 446 | 0.060 |
Why?
|
| Poisson Distribution | 3 | 2011 | 85 | 0.060 |
Why?
|
| Linear Models | 3 | 2015 | 204 | 0.060 |
Why?
|
| Interviews as Topic | 1 | 2006 | 324 | 0.060 |
Why?
|
| Choice Behavior | 1 | 2005 | 45 | 0.060 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2005 | 1 | 0.060 |
Why?
|
| Goals | 1 | 2005 | 28 | 0.060 |
Why?
|
| Health Services Research | 1 | 2006 | 201 | 0.060 |
Why?
|
| Breast Diseases | 1 | 2005 | 18 | 0.050 |
Why?
|
| Education, Medical, Continuing | 1 | 2005 | 32 | 0.050 |
Why?
|
| Sex Distribution | 3 | 2011 | 174 | 0.050 |
Why?
|
| Epidemiological Monitoring | 2 | 2015 | 22 | 0.050 |
Why?
|
| Body Mass Index | 1 | 2009 | 959 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2019 | 302 | 0.050 |
Why?
|
| Obesity | 2 | 2014 | 821 | 0.050 |
Why?
|
| Self Care | 1 | 2005 | 144 | 0.050 |
Why?
|
| Cholesterol, LDL | 2 | 2015 | 117 | 0.050 |
Why?
|
| Patient Participation | 1 | 2005 | 124 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2019 | 363 | 0.050 |
Why?
|
| Bacterial Vaccines | 1 | 2023 | 9 | 0.050 |
Why?
|
| Alcoholism | 1 | 2007 | 333 | 0.050 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2023 | 26 | 0.050 |
Why?
|
| Oxygen | 1 | 2023 | 15 | 0.050 |
Why?
|
| Respiration, Artificial | 1 | 2023 | 38 | 0.050 |
Why?
|
| Dexamethasone | 1 | 2022 | 11 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2022 | 11 | 0.050 |
Why?
|
| Health Care Costs | 1 | 2004 | 211 | 0.050 |
Why?
|
| Morphine Derivatives | 1 | 2022 | 4 | 0.050 |
Why?
|
| Warfarin | 1 | 2023 | 72 | 0.050 |
Why?
|
| Cluster Analysis | 1 | 2022 | 90 | 0.050 |
Why?
|
| Immunization Programs | 1 | 2002 | 64 | 0.050 |
Why?
|
| Public Opinion | 1 | 2002 | 3 | 0.050 |
Why?
|
| Physical Examination | 1 | 2002 | 20 | 0.050 |
Why?
|
| Antigens | 1 | 2021 | 7 | 0.040 |
Why?
|
| Prognosis | 2 | 2017 | 609 | 0.040 |
Why?
|
| Gestational Age | 1 | 2021 | 119 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2002 | 147 | 0.040 |
Why?
|
| Chickenpox Vaccine | 1 | 2021 | 91 | 0.040 |
Why?
|
| Preventive Health Services | 1 | 2002 | 147 | 0.040 |
Why?
|
| Mass Screening | 1 | 2006 | 693 | 0.040 |
Why?
|
| Michigan | 1 | 2020 | 27 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 37 | 0.040 |
Why?
|
| Health | 1 | 2020 | 32 | 0.040 |
Why?
|
| Prisons | 1 | 2020 | 29 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2011 | 210 | 0.040 |
Why?
|
| Medical Informatics | 1 | 2019 | 33 | 0.040 |
Why?
|
| Motivation | 1 | 2020 | 112 | 0.040 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 193 | 0.040 |
Why?
|
| Muramidase | 1 | 1998 | 1 | 0.030 |
Why?
|
| Proteolipids | 1 | 1998 | 1 | 0.030 |
Why?
|
| Terbutaline | 1 | 1998 | 1 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Proteins | 1 | 1998 | 1 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein A | 1 | 1998 | 1 | 0.030 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 1998 | 1 | 0.030 |
Why?
|
| Cell Size | 1 | 1998 | 1 | 0.030 |
Why?
|
| Fibroblast Growth Factor 7 | 1 | 1998 | 1 | 0.030 |
Why?
|
| Fibroblast Growth Factor 10 | 1 | 1998 | 1 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1998 | 2 | 0.030 |
Why?
|
| Culture Media | 1 | 1998 | 2 | 0.030 |
Why?
|
| Glycoproteins | 1 | 1998 | 2 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1998 | 8 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 1998 | 5 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 1998 | 5 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 1998 | 14 | 0.030 |
Why?
|
| Phospholipids | 1 | 1998 | 3 | 0.030 |
Why?
|
| Rats | 1 | 1998 | 33 | 0.030 |
Why?
|
| Hydrocortisone | 1 | 1998 | 17 | 0.030 |
Why?
|
| Multilevel Analysis | 1 | 2017 | 11 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 308 | 0.030 |
Why?
|
| Censuses | 1 | 2017 | 28 | 0.030 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2017 | 22 | 0.030 |
Why?
|
| Age Distribution | 2 | 2008 | 230 | 0.030 |
Why?
|
| Animals | 1 | 1998 | 285 | 0.030 |
Why?
|
| Minnesota | 1 | 2017 | 51 | 0.030 |
Why?
|
| Northwestern United States | 1 | 2017 | 53 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 50 | 0.030 |
Why?
|
| Acute Disease | 2 | 2008 | 147 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2008 | 137 | 0.030 |
Why?
|
| Pregnancy Trimesters | 1 | 2016 | 29 | 0.030 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2016 | 56 | 0.030 |
Why?
|
| Precipitating Factors | 1 | 2015 | 2 | 0.030 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2016 | 98 | 0.030 |
Why?
|
| Exercise Test | 1 | 2015 | 41 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 59 | 0.030 |
Why?
|
| Administration, Inhalation | 1 | 2015 | 39 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 19 | 0.030 |
Why?
|
| Information Storage and Retrieval | 1 | 2015 | 17 | 0.030 |
Why?
|
| Albuminuria | 1 | 2015 | 39 | 0.030 |
Why?
|
| Survival Rate | 1 | 2015 | 252 | 0.030 |
Why?
|
| Blood Pressure Determination | 1 | 2015 | 56 | 0.030 |
Why?
|
| International Classification of Diseases | 1 | 2015 | 85 | 0.030 |
Why?
|
| Anti-Asthmatic Agents | 1 | 2015 | 88 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2015 | 158 | 0.030 |
Why?
|
| Pharmacists | 1 | 2014 | 50 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 104 | 0.030 |
Why?
|
| Capitation Fee | 1 | 2013 | 10 | 0.030 |
Why?
|
| Sulfonylurea Compounds | 1 | 2013 | 32 | 0.030 |
Why?
|
| Geography | 1 | 2013 | 38 | 0.020 |
Why?
|
| Reimbursement, Incentive | 1 | 2013 | 21 | 0.020 |
Why?
|
| Natural Language Processing | 1 | 2014 | 60 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2014 | 283 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2012 | 12 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2012 | 4 | 0.020 |
Why?
|
| Decision Trees | 1 | 2012 | 18 | 0.020 |
Why?
|
| Models, Economic | 1 | 2012 | 17 | 0.020 |
Why?
|
| Cost Savings | 1 | 2012 | 20 | 0.020 |
Why?
|
| Hyperlipidemias | 1 | 2011 | 44 | 0.020 |
Why?
|
| Utilization Review | 1 | 2011 | 42 | 0.020 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 18 | 0.020 |
Why?
|
| Medically Uninsured | 1 | 2011 | 41 | 0.020 |
Why?
|
| Centers for Disease Control and Prevention (U.S.) | 1 | 2011 | 32 | 0.020 |
Why?
|
| Psychiatry | 1 | 2011 | 22 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2012 | 88 | 0.020 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 87 | 0.020 |
Why?
|
| Diabetes, Gestational | 1 | 2014 | 328 | 0.020 |
Why?
|
| Receptors, Angiotensin | 1 | 2010 | 3 | 0.020 |
Why?
|
| Arkansas | 1 | 2010 | 6 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2010 | 14 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2010 | 22 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 19 | 0.020 |
Why?
|
| Decision Making | 1 | 2011 | 177 | 0.020 |
Why?
|
| Psychometrics | 1 | 2010 | 119 | 0.020 |
Why?
|
| Heart Failure | 1 | 2015 | 414 | 0.020 |
Why?
|
| Psychotherapy | 1 | 2010 | 56 | 0.020 |
Why?
|
| Health Services Accessibility | 1 | 2011 | 269 | 0.020 |
Why?
|
| Splenectomy | 1 | 2008 | 2 | 0.020 |
Why?
|
| Platelet Count | 1 | 2008 | 9 | 0.020 |
Why?
|
| Multicenter Studies as Topic | 1 | 2008 | 80 | 0.020 |
Why?
|
| Affective Symptoms | 1 | 2007 | 5 | 0.020 |
Why?
|
| Somatoform Disorders | 1 | 2007 | 6 | 0.020 |
Why?
|
| Suburban Population | 1 | 2007 | 3 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2007 | 15 | 0.020 |
Why?
|
| Reference Values | 1 | 2007 | 86 | 0.020 |
Why?
|
| Probability | 1 | 2007 | 70 | 0.020 |
Why?
|
| Family Practice | 1 | 2007 | 41 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2007 | 107 | 0.020 |
Why?
|
| Markov Chains | 1 | 2006 | 22 | 0.020 |
Why?
|
| Haemophilus Vaccines | 1 | 2005 | 19 | 0.010 |
Why?
|
| Health Education | 1 | 2006 | 82 | 0.010 |
Why?
|
| Pneumococcal Infections | 1 | 2005 | 43 | 0.010 |
Why?
|
| CD-ROM | 1 | 2005 | 3 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2008 | 398 | 0.010 |
Why?
|
| Nonlinear Dynamics | 1 | 2005 | 7 | 0.010 |
Why?
|
| Computer-Assisted Instruction | 1 | 2005 | 10 | 0.010 |
Why?
|
| Diet, Fat-Restricted | 1 | 2005 | 36 | 0.010 |
Why?
|
| Fruit | 1 | 2005 | 79 | 0.010 |
Why?
|
| Vegetables | 1 | 2005 | 88 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 45 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2004 | 50 | 0.010 |
Why?
|
| Medical Record Linkage | 1 | 2004 | 33 | 0.010 |
Why?
|
| Mental Health | 1 | 2006 | 163 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2002 | 46 | 0.010 |
Why?
|
| Poverty Areas | 1 | 2002 | 21 | 0.010 |
Why?
|
| Postal Service | 1 | 2002 | 72 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2002 | 368 | 0.010 |
Why?
|